DBV TECHNOLOGIES SA-SPON ADR (DBVT)
US23306J2006 - ADR
DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN:...
DBV Technologies annonce son intention de modifier le ratio d'ADS
Châtillon, France, le 11 novembre (22 :30 CET) 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV –...
DBV Technologies Reports Third Quarter 2024 Financial Results
DBV Technologies Reports Third Quarter 2024 Financial Results
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4...
DBV Technologies publie ses résultats financiers du troisième trimestre 2024
Châtillon, France, le 6 novembre (22 :30 CET) 2024 DBV Technologies publie ses résultats financiers du troisième trimestre 2024 DBV clôture le...
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to...
DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe
Châtillon, France, le 22 octobre (22 :15 CEST) 2024 DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en...
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN:...
DBV Technologies participera au prochain congrès de l'ACAAI 2024
Châtillon, France, le 18 octobre (22 :30 CEST) 2024 DBV Technologies participera au prochain congrès de l'ACAAI 2024 DBV Technologies (Euronext...
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024 (Article 223-16 du Règlement Général...
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its...
DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE
Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a...
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies...
DBV Technologies participera à la 26e conférence annuelle H.C. Wainwright Global Investment
Châtillon, France, 4 septembre, 2024 (22:30 CET) DBV Technologies participera à la 26e conférence annuelle H.C. Wainwright Global Investment DBV...
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General...
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2024 (Article 223-16 du Règlement Général...
DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024
DBVT stock results show that DBV Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DBV Technologies (NASDAQ:DBVT) just reported results for the second quarter of ...
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies publie son Rapport Financier Semestriel 2024 ― Modalités de mise à disposition ou de consultation
Châtillon, France, le 30 juillet 2024 DBV Technologies publie son Rapport Financier Semestriel 2024 ― Modalités de mise à disposition ou de consultation ...
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV...
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and...
DBV Technologies présente les dernières avancées du programme Viaskin Peanut chez les enfants de 4 à 7 ans et les tout-petits de 1 à 3 ans et publie ses résultats financiers du deuxième trimestre et premier semestre 2024.
DBV Technologies présente les dernières avancées du programme Viaskin Peanut chez les enfants de 4 à 7 ans et les tout-petits de 1 à 3 ans et publie ses...